TABLE IV.

Results of Recent Randomized Studies in Newly Diagnosed Myeloma

Trial	Regimen	No. of patients	Overall response rate (%)	CR plus VGPR (%)	Progression-free survival (median in years)	P value for progression-free survival	3-year overall survival rate (%)a	Overall survival (median in years)	P value for overall survival
Rajkumar et al. [55]	RD	223	81	50	19.1		75	NR
	Rd	222	70	40	25.3	0.026	74	NR	0.47
Harousseau et al. [70]	VAD	242	63	15	30		77	NR
	VD	240	79	38	36	0.06	81	NR	0.46
Cavo et al. [62]	TD	238	79	28	40		84	NR
	VTD	236	93	62	NR	0.006	86	NR	0.3
Moreau et al. [71]	VD	99	81	35	N/A		N/A	N/A
	VTD	100	90	51	N/A		N/A	N/A
Facon et al. [57]	MP	196	35	7	17.8		48	33.2
	Mel 100	126	65	43	19.4		52	38.3
	MPT	125	76	47	27.5	<0.001	66	51.6	<0.001
Hulin et al. [58]	MP + Placebo	116	31	7	18.5		40	29.1
	MPT	113	62	21	24.1	0.001	55	44	0.028
Wijermans et al. [72]	MP	168	45	10	9		43	31
	MPT	165	66	27	13	<0.001	55	40	0.05
Palumbo et al. [73]	MP	164	48	11	14.5		65	47.6
	MPT	167	69	29	21.8	0.004	65	45	0.79
Waage et al. [74]	MP + Placebo	175	33	7	14		43	32
	MPT	182	34	23	15	NS	43	29	0.16
San Miguel et al.b[61,75]	MP	331	35	8	16.6		54	43
	VMP	337	71	41	24	<0.001	69	NR	<0.001

^aEstimated from survival curves when not reported.

^bProgression-free survival not reported, numbers indicate time to progression. Abbreviations: CR, complete response; MP, melphalan plus prednisone; MPT, melphalan plus prednisone plus thalidomide; N/A, not available; NS, not significant; Rd, lenalidomide plus dexamethasone; TD, thalidomide plus dexamethasone; VGPR, very good partial response; VMP, bortezomib plus melphalan plus prednisone; VTD, bortezomib, thalidomide, dexamethasone.